Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05046886 · ClinicalTrials.gov registry record · NA
Personalized Dietary Management in Type 2 Diabetes
A NA study of Type 2 Diabetes, sponsored by NYU Langone Health.
- Active
- Registry status
- NA
- Development phase
- 294
- Enrollment target
- 1
- Study location
NCT05046886: Active NA study of Type 2 Diabetes, sponsored by NYU Langone Health.
NCT05046886 is a NA study of Type 2 Diabetes that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 294 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05046886, a NA study of Type 2 Diabetes, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 294 participants
- Enrollment target
- 1
- Study location
Study Summary
In a randomized trial of 255 participants with early-stage T2D, participants will be randomized to 1 of 3 groups: Standardized, Personalized, or a Usual Care Control (UCC). In the first phase, participants will be randomized with equal allocation to these 3 groups. In the second phase (current phase), the remaining participants will be randomized with equal allocation to the Standardized and UCC groups.
Primary Outcome
MAGE will be evaluated via a continuous glucose monitor (CGM), which captures interstitial glucose readings every 15 minutes for up to 2 weeks from a sensor inserted into the participant's upper arm.
Conditions Studied
Interventions
- BEHAVIORAL Standardized
- BEHAVIORAL Usual Care Control (UCC)
- BEHAVIORAL Personalized Guidance to Minimize Postprandial Glycemic Response (PPGR)
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2025-11-30 |
| Phase | NA |
What the registry record for NCT05046886 still lists
NCT05046886 is an interventional study that assigns participants to a tested intervention. The registered 294 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Standardized is the first listed.
NCT05046886 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05046886 about?
NCT05046886 is a clinical study titled "Personalized Dietary Management in Type 2 Diabetes". In a randomized trial of 255 participants with early-stage T2D, participants will be randomized to 1 of 3 groups: Standardized, Personalized, or a Usual Care Control (UCC). In the first phase, participants will be randomized with equal allocation to these 3 groups. In the second phase (current phase...
What is the current status of trial NCT05046886?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 294 participants. The study started on 2021-12-14. Estimated completion is 2025-11-30.
What conditions does trial NCT05046886 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT05046886?
The interventions under investigation include: Standardized (BEHAVIORAL), Usual Care Control (UCC) (BEHAVIORAL), Personalized Guidance to Minimize Postprandial Glycemic Response (PPGR) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05046886?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05046886 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05046886's enrollment target sits among peer trials
294 72nd of 327 higher than 256 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06262113 · 294 participants · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI